219862-14-3Relevant articles and documents
NOVEL N-HYDROXY-BENZAMIDS FOR THE TREATMENT OF CANCER
-
, (2012/03/27)
The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt, ester or stereoisomer thereof, wherein R1 to R3 and X have the significances given herein. The present invention is also directed to proc
ANTAGONISTS OF THE TRPV1 RECEPTOR AND USES THEREOF
-
Page/Page column 30, (2008/12/06)
The present application is directed to compounds that are TRPV1 antagonists and have formula (I) wherein variables Ar1, L1, R1, R2, R3, R4, R5, Y1, Y2, and Y3, are as defined in the description, which are useful for treating disorders caused by or exacerbated by vanilloid receptor activity.
Design, synthesis, and structure-activity relationships of tetrahydroquinoline-based farnesyltransferase inhibitors
Lombardo, Louis J.,Camuso, Amy,Clark, John,Fager, Krista,Gullo-Brown, Johnni,Hunt, John T.,Inigo, Ivan,Kan, David,Koplowitz, Barry,Lee, Francis,McGlinchey, Kelly,Qian, Ligang,Ricca, Carolyn,Rovnyak, George,Traeger, Sarah,Tokarski, John,Williams, David K.,Wu, Laurence I.,Zhao, Yufen,Manne, Veeraswamy,Bhide, Rajeev S.
, p. 1895 - 1899 (2007/10/03)
Tetrahydroquinoline-based small molecule inhibitors of farnesyltransferase (FT) have been identified. Lead compounds were shown to have nanomolar to sub-nanomolar activity in biochemical assays with excellent potency in a Ras-mutated cellular reversion as